PB2452 Phase 3 Ticagrelor Reversal Study (PB2452-PT-CL-0004

Grants and Contracts Details

StatusActive
Effective start/end date1/7/218/21/24

Funding

  • SFJ Pharmaceuticals X Ltd: $5,750.00